IRIS
PUCCINI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.677
NA - Nord America 1.252
SA - Sud America 439
EU - Europa 308
AF - Africa 49
Totale 3.725
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.200
SG - Singapore 932
BR - Brasile 345
CN - Cina 297
VN - Vietnam 191
IT - Italia 85
HK - Hong Kong 73
FR - Francia 45
IN - India 44
DE - Germania 37
AR - Argentina 30
GB - Regno Unito 27
BD - Bangladesh 23
MX - Messico 22
CA - Canada 20
EC - Ecuador 20
AT - Austria 18
ID - Indonesia 18
TR - Turchia 16
CL - Cile 13
PL - Polonia 13
ES - Italia 12
FI - Finlandia 11
IQ - Iraq 11
MA - Marocco 11
CO - Colombia 10
NL - Olanda 10
ZA - Sudafrica 10
JP - Giappone 9
RU - Federazione Russa 9
EG - Egitto 8
SA - Arabia Saudita 8
PH - Filippine 7
SE - Svezia 7
UY - Uruguay 7
VE - Venezuela 7
DZ - Algeria 5
JM - Giamaica 5
KZ - Kazakistan 5
LT - Lituania 5
PY - Paraguay 5
UA - Ucraina 5
KE - Kenya 4
TN - Tunisia 4
CY - Cipro 3
NP - Nepal 3
PK - Pakistan 3
QA - Qatar 3
RS - Serbia 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LU - Lussemburgo 2
LV - Lettonia 2
MY - Malesia 2
OM - Oman 2
PS - Palestinian Territory 2
RO - Romania 2
TH - Thailandia 2
ZM - Zambia 2
AD - Andorra 1
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CH - Svizzera 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
IL - Israele 1
IM - Isola di Man 1
KG - Kirghizistan 1
KR - Corea 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
MK - Macedonia 1
MN - Mongolia 1
NG - Nigeria 1
NO - Norvegia 1
PE - Perù 1
PT - Portogallo 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
YE - Yemen 1
Totale 3.725
Salva come PNG Salva come JPEG
Città #
Dallas 498
Singapore 397
Ashburn 178
The Dalles 151
Beijing 142
San Jose 141
Ho Chi Minh City 81
Hong Kong 73
Hanoi 32
São Paulo 29
Shanghai 22
Los Angeles 20
Milan 18
Assago 16
Naples 16
Chennai 14
New York 14
Curitiba 13
Mexico City 12
Helsinki 11
Orem 11
Belo Horizonte 10
Guayaquil 10
Nuremberg 9
Rio de Janeiro 9
Warsaw 9
Hải Dương 8
Jakarta 8
London 8
Montreal 8
Tongling 8
Ankara 7
Biên Hòa 7
Brasília 7
Haiphong 7
Porto Alegre 7
Quito 7
Tokyo 7
Vienna 7
Baghdad 6
Montevideo 6
Rome 6
Stockholm 6
Can Tho 5
Dhaka 5
Goiânia 5
Hillsboro 5
Johannesburg 5
Manaus 5
Paris 5
Reston 5
Ribeirão Preto 5
Atlanta 4
Bogotá 4
Brooklyn 4
Campinas 4
Chicago 4
Da Nang 4
Delhi 4
Denver 4
Frankfurt am Main 4
Ha Long 4
Lấp Vò 4
Mumbai 4
Santa Clara 4
São José dos Campos 4
Toronto 4
Astana 3
Cairo 3
Camaçari 3
Casablanca 3
Chengdu 3
Des Moines 3
Doha 3
Genoa 3
Guarulhos 3
Hangzhou 3
Istanbul 3
Joinville 3
Limburg an der Lahn 3
Manchester 3
Nairobi 3
New Delhi 3
Quận Bình Thạnh 3
Riyadh 3
Roden 3
Roubaix 3
Santiago 3
Seattle 3
Tashkent 3
Turin 3
Volta Redonda 3
Alexandria 2
Amsterdam 2
Antofagasta 2
Belgrade 2
Belém 2
Berlin 2
Betim 2
Bologna 2
Totale 2.252
Salva come PNG Salva come JPEG
Nome #
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life 417
A new prognostic and predictive tool for shared decision making in stage III colon cancer 101
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy 65
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials 64
Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients 62
Streamlining the diagnostic pathway for Lynch syndrome in colorectal cancer patients: a 10-year experience in a single Italian Cancer Center 57
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 57
Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer 57
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 54
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort 54
Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors 54
Colorectal cancer: epigenetic alterations and their clinical implications 53
Lynch Syndrome: From Multidisciplinary Management to Precision Prevention 52
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAFV600E-mutated metastatic colorectal cancer treated with targeted therapy 52
Barriers and Facilitators in Diagnostic Pathways That Align Universal Tumor Screening and Mainstream Genetic Testing for Lynch Syndrome in Colorectal Cancer: Protocol for a Scoping Review With a Narrative Synthesis 50
Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting 49
Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets 49
Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study 49
Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer 48
BRAFV600E immunohistochemistry can reliably substitute BRAF molecular testing in the Lynch syndrome screening algorithm in colorectal cancer 47
New perspectives for colorectal cancer 46
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective 45
Research training, barriers, and career development needs of early-career investigators in oncology: an EORTC survey-based study 45
Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) 44
WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype 44
Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis 44
Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma 43
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3 43
First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy? 42
Cisplatin-related Atrial Fibrillation during PEB Chemotherapy for Testicular Seminoma: A Case Report 42
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer 42
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset 42
Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 42
Redefining Colorectal Cancer by Tumor Biology 40
Tackling hurdles in front of young clinical investigators in oncology – Results from an international survey 40
Management of Advanced Small Bowel Cancer 40
Young Patients with Colorectal Cancer: Risk, Screening, and Treatment 40
Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients 40
A polymorphism within the Vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/ bevacizumab or FOLFIRI/Cetuximab 39
Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study 39
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial 39
Impact of Sociodemographic Disparities and Insurance Status on Survival of Patients with Early-Onset Colorectal Cancer 38
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers 38
Molecular profile of BRCA-mutated biliary tract cancers 37
What We Know About Stage II and III Colon Cancer: It's Still Not Enough 37
Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand? 37
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies 37
The impact of ARID1A mutation on molecular characteristics in colorectal cancer 36
Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions 36
B cell and B cell-related pathways for novel cancer treatments 36
Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study 36
Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer 36
The role of tumor angiogenesis as a therapeutic target in colorectal cancer 35
Microsatellite-Instability-High Advanced Colorectal Cancer 35
From walls to wonder: Talking about spaces tailored for adolescents and young adults with cancer 34
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM) 34
Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer 34
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma 33
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy 33
ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care? 33
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 33
The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer 33
Outlooks on Epstein-Barr virus associated gastric cancer 32
Molecular Variances Between Right- and Left-sided Colon Cancers 31
Maintenance Olaparib for Metastatic Pancreatic Cancer 31
Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens 30
The urgent need to improve the tools to assess clinical benefit and value of cancer treatment 30
Safety and Tolerability of c-MET Inhibitors in Cancer 30
The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives 30
Metastatic sarcoma: tailored strategies for a heterogeneous disease 30
Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives 29
Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients 29
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets 29
Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives 28
Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors 28
Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers 28
Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients 28
Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence? 28
Routinely Updating Patients With Cancer About Variant of Uncertain Significance Reclassifications: A Premature Responsibility for Community Oncologists 27
Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3 27
Editorial: New therapeutic approaches in microsatellite stable colorectal cancer patients 27
Practice-changing updates in the adjuvant and metastatic setting 26
Reliability of patient-reported toxicities during adjuvant chemotherapy 25
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system 23
Fertility Preservation Practices and Gastrointestinal (GI) Oncologist in Europe: A Pan-European study 21
The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials 20
Universal tumor screening and mainstream genetic testing for Lynch syndrome in colorectal cancer: a scoping review of barriers and facilitators 16
Prognostic impact of pathological complete response and response-adapted outcomes in patients with gastroesophageal adenocarcinoma treated with neoadjuvant or perioperative treatments: a multicentric cohort study 13
Impact of RAS/BRAF V600E mutations on the tumor immune microenvironment in mismatch repair deficient /microsatellite instability colorectal cancers 13
Totale 3.822
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.377
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.377
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202412 0 0 0 0 0 0 0 0 0 4 4 4
2024/2025793 1 2 1 4 1 123 79 109 74 182 75 142
2025/20263.017 362 228 546 389 91 158 585 208 283 167 0 0
Totale 3.822